CAS No.: | 1415456-99-3 |
---|---|
Formula: | C187h291n45o59 |
EINECS: | Cagrilintide |
Type: | Pharmaceutical Intermediates |
Appearance: | Powder |
Quality: | Technical |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product Information
Product Name: Cagrilintide
CAS No.: 1415456-99-3
Purity: >99.0%
Molecular Formula: C187H291N45O59
Molecular Weight: 4409g/mol
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance: White Lyophilized powder
Reconstitution: Required
Storage:After reconstitution store at 2°C - 8°C
Description:
Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake.
CagriSema is a combination medication of the receptor agonist sema and cagrilintide. Cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insu, amylin makes people feel satiated or full after eating a meal.
CagriSema is a once-weekly injection of sema and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment.
Measure |
CagriSema |
Sema |
Cagrilinitide |
Number of participants |
31 |
31 |
30 |
Average decrease in A1C |
2.2% |
1.8% |
0.9% |
Percentage of participants with an A1C ≤ 6.5% |
75% |
48% |
17% |
Average decrease in body weight |
15.6% |
5.1% |
8.1% |
Average increase in time in range |
43% | 43.6% | 14.8% |
Suppliers with verified business licenses